Premium
Structures of Hsp90α and Hsp90β bound to a purine‐scaffold inhibitor reveal an exploitable residue for drug selectivity
Author(s) -
Huck John D.,
Que Nanette L. S.,
Sharma Sahil,
Taldone Tony,
Chiosis Gabriela,
Gewirth Daniel T.
Publication year - 2019
Publication title -
proteins: structure, function, and bioinformatics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.699
H-Index - 191
eISSN - 1097-0134
pISSN - 0887-3585
DOI - 10.1002/prot.25750
Subject(s) - hsp90 , residue (chemistry) , chemistry , selectivity , hsp90 inhibitor , hydrogen bond , stereochemistry , biochemistry , combinatorial chemistry , gene , organic chemistry , molecule , heat shock protein , catalysis
Hsp90α and Hsp90β are implicated in a number of cancers and neurodegenerative disorders but the lack of selective pharmacological probes confounds efforts to identify their individual roles. Here, we analyzed the binding of an Hsp90α‐selective PU compound, PU‐11 ‐trans , to the two cytosolic paralogs. We determined the co‐crystal structures of Hsp90α and Hsp90β bound to PU‐11 ‐trans , as well as the structure of the apo Hsp90β NTD. The two inhibitor‐bound structures reveal that Ser52, a nonconserved residue in the ATP binding pocket in Hsp90α, provides additional stability to PU‐11 ‐trans through a water‐mediated hydrogen‐bonding network. Mutation of Ser52 to alanine, as found in Hsp90β, alters the dissociation constant of Hsp90α for PU‐11 ‐trans to match that of Hsp90β. Our results provide a structural explanation for the binding preference of PU inhibitors for Hsp90α and demonstrate that the single nonconserved residue in the ATP‐binding pocket may be exploited for α/β selectivity.